Costs and benefits of HIV-1 antibody testing of donated blood

Gregory M. Gelles

Journal of Policy Analysis and Management, 1993, vol. 12, issue 3, 512-531

Abstract: Costs and benefits of the testing protocol for screening donated blood for the HIV-1 virus are evaluated. Estimates are made of the number of HIV-1 infections and cases of AIDS prevented in a year by blood testing, as well as the costs of providing this risk reduction. The risk reduction provided by alternative tests such as the HIV-1 antigen test is also discussed. The value of the risk reduction provided by blood testing is generated utilizing willingness-to-pay value-of-life estimates. The findings indicate that the present testing protocol is cost beneficial and support the FDA decision not to recommend the HIV-1 antigen test for use in donor testing. Policy decisions concerning present and future testing protocols are discussed, and implications for broadening our model to include indirect benefits of donor testing are evaluated.

Date: 1993
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2307/3325304 Link to full text; subscription required (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:jpamgt:v:12:y:1993:i:3:p:512-531

DOI: 10.2307/3325304

Access Statistics for this article

More articles in Journal of Policy Analysis and Management from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().